利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

2601 条记录 (耗时 0.04 秒)

    Methods and compositions for direct detection of DNA damage
    82.
    发明公开
    Methods and compositions for direct detection of DNA damage 有权
    Verfahrenfürden direkten Nachweis von DNA-Schäden

    公开(公告)号：EP2604702A1

    公开(公告)日：2013-06-19

    申请号：EP12189330.9

    申请日：2009-09-08

    申请人： The University of Chicago

    发明人： Schwartz, David ,  Kron, Stephen

    IPC分类号： C12Q1/68 ,  G01N33/52

    CPC分类号： G01N33/582 ,  G01N33/5308 ,  G01N2800/40 ,  Y10T436/143333

    摘要： The present invention is a method for detecting the extent of DNA damage in a subject suspected of having DNA damage wherein the damage results in the formation of aldehyde moieties in DNA comprising, obtaining a DNA sample from the subject, combining the DNA sample with a fluorescent, chromogenic, pro-fluorescent or pro-chromogenic hydrazine compound to from a fluorescent DNA, detecting the presence of the fluorescent DNA by monitoring the fluorescent emission and quantitating the fluorescent emission thereby determining the extent of DNA damage in the subject.

    摘要翻译： 本发明是用于检测疑似患有DNA损伤的受试者的DNA损伤程度的方法，其中所述损伤导致在DNA中形成醛部分，其包括：从受试者获得DNA样品，将DNA样品与荧光 ，显色性，前荧光或原色显色肼化合物，通过监测荧光发射和定量荧光发射来检测荧光DNA的存在，从而确定受试者中DNA损伤的程度。

    RNA targeting compounds and methods for making and using same
    84.
    发明公开
    RNA targeting compounds and methods for making and using same 有权
    RNA-Target-Verbindungen und Verfahren zu ihrer Herstellung und Verwendung

    公开(公告)号：EP2591795A1

    公开(公告)日：2013-05-15

    申请号：EP12178045.6

    申请日：2008-02-25

    申请人： The Research Foundation Of State University Of New York

    发明人： Disney, Matthew D.

    IPC分类号： A61K38/16

    CPC分类号： C07K4/00 ,  A61K31/7008 ,  C07D249/04 ,  C07K9/00 ,  C07K14/001 ,  Y10T436/143333

    摘要： Disclosed are RNA targeting compounds having the formula : wherein j is an integer from 1 to 100; each i is the same or different and is zero or an integer from 1 to 100; each Z 1 represents the same or different linking moiety; each R 1 is the same or different and represents an alkyl group or an aryl group; each Q 1 represents the same or different RNA binding ligand; Q 2 is an alkyl group; Q 3 is a halogen, an alkyl group, an aryl group, or an amine. Also disclosed are RNA targeting compounds that include a polymer backbone and two or more pendant RNA binding ligands that are bound to the polymer backbone. Methods for using the subject RNA targeting compounds to treat myotonic dystrophy and other diseases are also disclosed, as are compounds that can be used to prepare the subject RNA targeting compounds.

    摘要翻译： 公开了具有下式的RNA靶向化合物：其中j是1至100的整数; 每个i相同或不同，为零或1至100的整数; 每个Z 1表示相同或不同的连接部分; 每个R 1相同或不同，表示烷基或芳基; 每个Q 1代表相同或不同的RNA结合配体; Q 2是烷基; Q 3是卤素，烷基，芳基或胺。 还公开了RNA靶向化合物，其包括聚合物主链和结合至聚合物主链的两个或更多个侧挂RNA结合配体。 还公开了使用目标RNA靶向化合物来治疗强直性营养不良和其他疾病的方法，以及可用于制备目标RNA靶向化合物的化合物。

    Genetic markers of mental illness
    89.
    发明公开
    Genetic markers of mental illness 审中-公开
    精神疾病的遗传标记

    公开(公告)号：EP2570498A3

    公开(公告)日：2013-03-27

    申请号：EP12197037.0

    申请日：2009-01-02

    申请人： Suregene Llc

    发明人： Brennan, Mark David ,  Ramsey, Timothy Lynn

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/172 ,  G06F19/18 ,  Y02A90/26 ,  Y10T436/143333

    摘要： This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ) and methods of use thereof. In particular, in vitro methods of predicting a human subject's likely response to treatment with olanzapine, risperidone, perphenazine or ziprasidone, of selecting a treatment for schizophrenia comprising administration of olanzapine, risperidone, perphenazine or ziprasidone, comprising detecting a haplotype comprising one or more polymorphic markers in PPP3CA or markers in linkage desiquilbrium (LD) therewith, are provided.

    摘要翻译： 本发明涉及精神疾病的遗传标记，例如精神分裂症（SZ）及其使用方法。 具体而言，预测人受试者对用奥氮平，利培酮，奋乃静或齐拉西酮治疗可能的反应的体外方法，选择包括施用奥氮平，利培酮，奋乃静或齐拉西酮的精神分裂症的治疗，包括检测包含一种或多种多态性 提供了PPP3CA中的标记或与其连锁的标记（LD）。

    Genetic markers of mental illness
    90.
    发明公开
    Genetic markers of mental illness 有权
    Genetische MarkerfürGeisteskrankheit

    公开(公告)号：EP2570497A2

    公开(公告)日：2013-03-20

    申请号：EP12197030.5

    申请日：2009-01-02

    申请人： Suregene Llc

    发明人： Brennan, Mark David ,  Ramsey, Timothy Lynn

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/172 ,  G06F19/18 ,  Y02A90/26 ,  Y10T436/143333

    摘要： This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ) and methods of use thereof. In particular, in vitro methods of predicting a human subject's likely response to treatment with olanzapine, risperidone, quetiapine, perphenazine or ziprasidone, or of selecting a treatment for schizophrenia comprising administration of olanzapine, risperidone, quetiapine, perphenazine or ziprasidone, comprising detecting a haplotype comprising one or more polymorphic markers in PCDH15 or markers in linkage desiquilbrium (LD) therewith, are provided.

    摘要翻译： 本发明涉及精神疾病的遗传标记，例如精神分裂症（SZ）及其使用方法。 特别地，预测人受试者对奥氮平，利培酮，喹硫平，奋乃静或齐拉西酮治疗的可能反应的体外方法，或选择精神分裂症治疗，包括施用奥氮平，利培酮，喹硫平，奋乃静或齐拉西酮，其包括检测单体型 包括PCDH15中的一个或多个多态性标记或与其连接的二链烷酸（LD）的标记。